Gabriel Roberti, MD

EV/P delivers again!! Congrats to @MattGalsky , investigators and patients on EV/P showing prolonged EFS and OS compared to neoadjuvant gem/cis A pivotal moment indeed #GU26 @OncoAlert

Kidney day at #GU26 with many exciting posters from friends and colleagues:

@MarcMachaalani @ASCO @OncoAlert @DanaFarber_GU @eddy_saad @Chrislabaki1 @ZiadBakouny @BradMcG04 @IMG_Oncologists @OncoBellmunt @DrChoueiri Congratulations 👏🏽

Thrilled to present our work assessing real-world endpoints as surrogates for OS in metastatic bladder cancer! #GU26 @ASCO @OncoAlert @DanaFarber_GU

How to ever do sequencing studies with so many options coming down the pike? @Uromigos

An open access guide to renal medullary carcinoma: journals.sagepub.com/doi/epub/10.32…

My table on histologic subtypes of urinary tract tumors during #simposioSOGUG25 @sogug1 🔸 UC with mixed HS has different biological behaviors. 🔸 Mixed variants are managed (so far) as conventional UC with the exception of small cell. #bladdercancer

Eosinophilic Vacuolated Tumor (EVT) - generally considered benign/indolent & associated with MTOR pathway mutations. However, rarely it can be seen w/metastatic dz, as seen here (LVI+, LN+). 🔬@GU_Path_Society @IntSocUropath @AdanmaAnjiMD @Kiril_T_Can doi.org/10.1111/his.70…

Some prostate cancers evade therapy by transforming into aggressive neuroendocrine prostate cancer. New research highlights PROX1 as a key driver of this transformation and tumor growth, offering a potential treatment target. ➡️ bit.ly/4lEFHoD @CR_AACR @bajji @mishabeltran

60s M with a renal mass. What is your diagnosis? #PathTwitter @MGBpathology @MGHPathology

Ovarian Cancer jamanetwork.com/journals/jama/…

So proud to be part of this incredible research team! #KCRS25 #pathology #kidneycancer @kidneycan

Insightful discussions, cutting edge research, great speakers, multidisciplinary approach & an amazing audience- perfect #kidneycancer meeting @kidneycan #KCRS2025 #genomics #pathology #cancer

Molecular and Therapeutic Landscape of Non-Clear Cell Renal Cell Carcinoma: 🧬🧬🧬Diverse subtypes, unique genetics, unpredictable responses. @NatRevUrol @OncoAlert @kidneycan @IKCCorg @KidneyCancer @MehrazinMD rdcu.be/ewjT8

Enjoy Kidney Cancer's Special Pathology Edition. A great set of [open access] RCC reviews; also, sarcomas, benign tumors, molecular changes, familial syndromes, grading/staging. Great for patients, clinicians, researchers & pathologists.🔬#gupath @urotoday journals.sagepub.com/toc/kcaa/9/1_s…

This helpful infographic from @genome_gov explains the challenges of sequencing highly repetitive DNA and the technological advances that were needed to generate the first truly complete (gapless) human genome sequence. I encourage you to check it out! genome.gov/about-genomics…

Assessment and classification of sex cord‐stromal tumours of the testis: recommendations from the testicular sex cord‐stromal tumour (TESST) group, an Expert Panel of GUPS and ISUP- Acosta - Histopathology - Wiley Online Library #openaccess onlinelibrary.wiley.com/doi/10.1111/hi…

🧾 Cheat Sheet on Follow-up for NMIBC 🔹 Risk-based surveillance 🔹 Lifelong follow-up for high-risk patients 🔹 Role of cytology & markers 🔍 No substitute for cystoscopy Download Cheat Sheet: uroweb.org/guidelines/non… #BladderCancer #NMIBC #EAUguidelines

Unique pattern of an uncommon #testis tumor. What’s is your diagnosis #GUPath tweeps? #OnePicDx Answer in comment👇👇👇

Big news! Massachusetts General Hospital and Brigham and Women’s Hospital have been ranked #1 and #2 globally for research impact among healthcare institutions by the 2024 @NatureIndex. Proud to be part of a pathology department at the forefront of discovery! 🧪🔬 #PathTwitter